長安汽車:網傳入股華為車BU消息不實
市傳長安汽車(000625.SZ)入股華為智慧汽車解決方案業務(被稱為車BU、即Business Unit),《第一財經》引述長安汽車戰略規劃部門負責人表示,長安汽車與華為已建立戰略合作,雙方在阿維塔、深藍汽車上均有深度合作,但網絡流傳信息與事實不符。
早前網絡流傳消息指,車BU將從華為體系中剝離,整體估值2,500億元人民幣(下同),轉手後的第一大股東是重慶市國資委,而長安是唯一參與收購的車企,以375億獲得車BU的15%股權。
今年8月,有消息指華為計劃推動車BU獨立營運,並與重慶國資委商討合作,但其後華為澄清,傳聞與事實不符。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.